Biogen Inc vs LYFT Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while LYFT Inc trades at $17.5 (market cap $6.64B). The key difference: Biogen Inc is far larger — about 4.5× LYFT Inc's market cap, and Biogen Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | LYFT | |
|---|---|---|
Market Cap | $30.13B | $6.64B |
Sector | Health | Industrials |
52-Week High | $216.63 | $24.57 |
52-Week Low | $128.93 | $12.65 |
Enterprise Value | $37.20B | $6.11B |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →